Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHG3UR)

Drug Name

NOX-E36 Drug Info

Synonyms

Monocyte chemoattractant protein-1 ligand inhibitor(spiegelmer, diabetic complications), NOXXON; MCP-1 inhibitor (spiegelmer/injectable, diabetic complications/diabetic nephropathy), NOXXON

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMHG3UR

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Monocyte chemotactic and activating factor (CCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bindarit	DMS2GA1	Nephritis	GB40	Phase 3	[3]
Carlumab	DMAUN15	Pulmonary fibrosis	CB03.4	Phase 2	[4]
CNTO888	DMUBP0V	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
ABN-912	DMADKHB	Asthma	CA23	Discontinued in Phase 1	[6]
MCP-1	DMYEFKH	Rheumatoid arthritis	FA20	Preclinical	[7]
RS-504393	DMB9IPR	Chronic obstructive pulmonary disease	CA22	Preclinical	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monocyte chemotactic and activating factor (CCL2)	TTNAY0P	CCL2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01547897) NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria. U.S. National Institutes of Health.
2	Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923.
3	Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69.
4	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23.
5	CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62.
6	A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2387-92.
7	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
8	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.